New on NCI’s Websites for December 2017
December 27, 2017, by NCI Staff
NCI’s collection of cancer information products is constantly growing, so periodically we provide updates on new and updated content of interest to the cancer community.
Dr. Norman Sharpless Shares His Perspectives as NCI Director
In this archived video of his December 11 town hall meeting with NCI staff, NCI Director Norman Sharpless, M.D., discusses his broad views about cancer research, his initial impressions of NCI, and some of the exciting areas where NCI will be focusing its efforts in coming years.
Breast Cancer Research Facebook Live Event Video
On October 31, NCI’s Stan Lipkowitz, M.D., Ph.D., and Alexandra Zimmer, M.D., participated in a Facebook Live Event. The physician–researchers from the Center for Cancer Research’s Women’s Malignancies Branch discussed the latest research on advanced breast cancer.
Latest Edition of Pipeline Newsletter Available
NCI’s Division of Cancer Treatment and Diagnosis (DCTD) recently published a new issue of its newsletter, Pipeline News. The issue showcases DCTD’s Cancer Imaging Program, which recently celebrated its 20th anniversary. Additional articles include a staff profile, news about DCTD programs and activities, and new funding opportunities.
Video – DCEG: Uncovering the Causes of Cancer, Training Future Researchers
Researchers in NCI’s Division of Cancer Epidemiology and Genetics (DCEG) investigate the causes of cancer at the population level. This new video features DCEG scientists discussing aspects of their research in interviews done in conjunction with the American Society of Human Genetics.
Updated DCTD News & Events Pages
This has been a year full of noteworthy meetings and accomplishments for the Division of Cancer Treatment and Diagnosis. DCTD recently posted a collection of summaries of its 2017 meetings.
GAME-ON and OncoArray Video
This video discusses how the NCI-funded OncoArray Network investigates the genetic architecture and mechanisms underlying cancers of the breast, ovary, prostate, colon and rectum, and lung. The video also features the directors of NCI’s Division of Cancer Control and Population Sciences (DCCPS) and Division of Cancer Epidemiology and Genetics (DCEG), who offer their perspectives on the how the OncoArray Network and GAME-ON consortium can advance the understanding of how genetic variants contribute to the risk of these common cancers.
Updated Fact Sheets Available
Several NCI fact sheets were recently updated:
• Antioxidants and Cancer Prevention
• Harms of Cigarette Smoking and Health Benefits of Quitting
• Acrylamide in Food and Cancer Risk
• Antioxidants and Cancer Prevention
• Harms of Cigarette Smoking and Health Benefits of Quitting
• Acrylamide in Food and Cancer Risk
Video – HPV: Did You Know?
This new video discusses the human papillomavirus (HPV) and its relationship to cancer, including how it is transmitted, screening for HPV-caused abnormalities, and HPV vaccination.
PDQ Summary – Cognitive Impairment
A new Physician Data Query® summary for health professionals addresses cognitive impairments in people with non-central nervous system cancers. Cognitive impairment symptoms occur more frequently in cancer survivors than in healthy individuals.
New Drug Summaries Posted
Three new drug information summaries have been posted to the NCI website.
• Acalabrutinib (Calquence®) is approved to treat patients with relapsed or treatment-resistant mantle cell lymphoma.
• Valrubicin (Valstar®) is approved for bladder cancer that has not responded to previous treatment with bacillus Calmette-Guérin.
• Axicabtagene ciloleucel (Yescarta™) is a new CAR T-cell therapy approved for adult patients with certain types of B-cell non-Hodgkin lymphoma that has come back or not responded to two prior treatments.
• Acalabrutinib (Calquence®) is approved to treat patients with relapsed or treatment-resistant mantle cell lymphoma.
• Valrubicin (Valstar®) is approved for bladder cancer that has not responded to previous treatment with bacillus Calmette-Guérin.
• Axicabtagene ciloleucel (Yescarta™) is a new CAR T-cell therapy approved for adult patients with certain types of B-cell non-Hodgkin lymphoma that has come back or not responded to two prior treatments.
No hay comentarios:
Publicar un comentario